Customized Treatment Plan Weight loss is not a one-size-fits-all approach
Indications and Usage Wegovy (semaglutide) injection is indicated in combination with a reduced calorie diet and increased physical activity: To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight To reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbidity Wegovy (semaglutide) tablets are indicated in combination with a reduced calorie diet and increased physical activity to: Reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight Reduce excess body weight and maintain weight reduction long term in adults with obesity or with overweight in the presence of at least one weight-related comorbidity Limitations of Use: Concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products or with any GLP-1 receptor agonist is not recommended References Wegovy [package insert]
Therefore, further experimental exploration, clinical trials, case-control studies, and cohort studies are needed to validate the observed correlations
In general, its a good idea to reduce the amount of fiber you eat during the first few days after a semaglutide injection
Gastrointestinal side effects Both compounds cause GI side effects
GLP-1 receptor agonists bind to GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion whilst simultaneously suppressing glucagon release from alpha cells
